Persistent hypercoagulable state in COVID-19: A case series of COVID-19 associated pulmonary embolism

Kok Hoe Chan, Su Lin Lim, Hamid Shaaban, Gunwant Guron, Jihad SlimJournal of Global Infectious Diseases 2021 13(1):38-41Coronavirus disease 2019 (COVID-19) has swept through the world with millions of cases and hundreds of thousands of deaths. COVID-19-associated coagulopathy has been recognized as the major cause of morbidity and mortality. To the best of our knowledge, a majority of the cases of coagulopathy have been reported in patients with moderate-to-severe COVID-19 and limited to observations during the recovery/postcytokine storm state. Herein, we report a case series of two patients with COVID-19 who developed pulmonary embolism in the late phase of the disease. This raised the hypothesis that the risk of hypercoagulability in patients with COVID-19 can persist until the recovery phase, which would warrant a follow-up with D-dimer and fibrinogen trending, as well as postdischarge thromboprophylaxis for at least 2 weeks during the recovery phase.
Source: Journal of Global Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research